An observational study in Down Syndrome (Trisomy 21), Neuropsychology and Cognitive Aging, sponsored by Central Hospital, Nancy, France. Not yet recruiting at 1 site in France. Open to participants aged 25 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-02.
Sponsored by Central Hospital, Nancy, France · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Down Syndrome with a site in France — 12 open to participants now, 12 under way, none of them phase 3. Down Syndrome · France.
Among the 40 studies in Down Syndrome with a site in France, this one is the 19th largest by planned enrollment of the 23 observational ones that give a count, is one of 5 that started in 2025, is one of 23 observational ones, reaches primary completion later than 2 of the 11 other live ones, and was the 35th registered.
439 studies on the registry are indexed under Down Syndrome; 99 are open to participants now.
Browse Down Syndrome studies →12 of the 40 studies in Down Syndrome with a site in France are open now. Recruiting first, the newest first:
Hospices Civils de Lyon · Sites in France
Ages 3–29 · Healthy volunteers
Hospices Civils de Lyon · Sites in France
Ages 5 mo–6 mo
Aelis Farma · Sites in France, Italy, Spain
Ages 16–32
Hôpital le Vinatier · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 3–12
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 74 Down Syndrome studies recruiting now, 14 (19%) set no upper age limit and 57 (77%) stop at 75 or younger; 60 take children under 18; 19 take healthy volunteers.
This study: 25 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 2
First in 2000; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 158 across 145 observational studies indexed under Down Syndrome.
Median enrollment 150 across the 17 interventional studies, 100 across the 23 observational. Of the 24 that completed or were terminated, 1 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 40 have an industry lead sponsor. The 10 most frequent:
Central Hospital, Nancy, France is the lead sponsor of 801 studies on the registry; 188 are open to participants now.
Central Hospital, Nancy, France has 2 studies filed under Down Syndrome — fewer than ten, so there is no comparison to draw.
3 of the studies in Down Syndrome with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06061562University Hospital, GrenobleDown Syndrome, Physical Activity and Sleep Apnea | 2026-12-31 |
| NCT05970965Assistance Publique - Hôpitaux de ParisPeriodontitis and Inflammation in Children With Down Syndrome/Trisomy 21: Study on Biological Samples | 2027-04-30 |
| NCT06866925Hôpital le VinatiertDCS for Catatonic Depression in Down Syndrome: A Pilot Study | 2027-08-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 40 studies in Down Syndrome with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to evaluate the acceptability ofpatients with trisomy 21 (T21) to perform the full battery of ENDI neurospychological tests and each of the subsets.
In this study, three types of population will be recruted : normotypic volunteers, patients with Intellectual Disability and patients T21carriers.
This study is separated into 2 phases :
Trisomy 21 is a genetic disease resulting from a chromosomal anomaly, due to a triplication, bringing the total number of chromosomes to 47. In addition to physical characteristics, adults with Trisomy 21 (T21) generally have an intelligence quotient (IQ) score suggesting mild (IQ: 50-69) to moderate (IQ: 35-49) intellectual disability (ID), and adaptive functional impairments corresponding to this level of ID severity. Progress in medical and social care has led to a significant increase in life expectancy for trisomy 21 patients. De Graaf, Buckley \& Skotko (2021) estimate the number of trisomy 21 patients in France at around 35,000, 42% of whom are aged 40 or over. According to Asselin (2005), by 2030, the number of people with intellectual disabilities (ID) aged over 60 should have doubled.
This raises questions about the ageing of this population, all the more so as it is likely to occur earlier, due to reduced neuronal reserve. For example, signs of aging appear 10 years earlier in people with ID, at around age 55. Moreover, this aging process is said to be accelerated Normal cognitive aging in trisomy 21 patients is poorly characterized in the literature; similarly, there is no consensus regarding prodromal signs of Alzheimer's Disease (AD) in T21. However, the presence of the supernumerary chromosome containing the APP (Amyloid Precursor Protein) gene increases the risk of developing AD: 20% of trisomy 21 patients aged 45 and over develop a major neurocognitive disorder (MNCD), and over 50% by the age of 55. T21 is now considered a genetic form of AD, similar to an autosomal dominant form. Identifying AD in this population is therefore a real challenge, especially as AD is identified as the cause of 70% of deaths in trisomy 21 patients.
In cognitive terms, the precursor signs of AD are impairment of memory and temporo-spatial orientation, followed by impairment of praxis, language and visuo-spatial skills. Other authors suggest an early decline in executive functions. More recently, Startin et al. (2019) show that memory and attention tests are more sensitive in detecting prodromal forms. Establishing a diagnosis of neurodegenerative disease in trisomy 21 patients is important for at least 3 reasons. People with intellectual disabilities are often treated with neuroleptics, whose use is not recommended in AD. It also contributes to the adaptation of medical and social care, as ageing disabled people with AD will experience less frequent difficulties, including behavioural changes. According to the Edinburgh Principles, it is important to "ensure that appropriate diagnostic, assessment and intervention resources and services are available to meet the individual needs and promote the healthy ageing of people with intellectual disabilities and cognitive impairment". Finally, at a time when promising pharmacological treatments for AD are emerging for neurotypical subjects, it seems crucial that trisomy 21 patients, who are more at risk of AD, should be diagnosed as early as possible so that they can ultimately benefit from these new therapies. Neuropsychological assessment plays a crucial role in the diagnostic process, as brain imaging and lumbar puncture for AD biomarkers in cerebrospinal fluid are not always feasible.
However, a number of problems remain:
Normotypical volunteers, patients with intellectual disability, and Trisomie 21 patients (T21) will be recruited by psychologists during a consultation in the Geriatrics Department of the University Hospital of Nancy, either through the Memory Resource and Research Center outpatient clinic or the day hospital. Volunteers and patients are generally referred by their general practitioner or another hospital department.
Inclusion Criteria:
Preliminary phase:
The inclusion criteria for the group of people with intellectual disabilities are as follows:
The inclusion criteria for the normotypic group are as follows:
Main phase:
Inclusion criteria are as follows:
Exclusion Criteria for both phases of the study are as follows:
Individuals referred to in Articles L.1121-5 to L.1121-7 of the French Public Health Code:
Trisomy 21 patients recruted on Main Phase will perform the ENDI tests in order to assess the acceptability of the subtests (individually) and the full neuropsychological battery
Diagnostic Test: ENDI (Neuropsychological Evaluation in Intellectual Disability)
Patients with Intellectual Disabilities recruted on Preliminary Phase will be will carry out the ENDI tests in order to evaluate subtest design, ergonomics, understanding of instructions and identify any malfunctions. The observations gathered will enable the principal investigator to refine the digital design of the battery in collaboration with the publishing company.
Diagnostic Test: ENDI (Neuropsychological Evaluation in Intellectual Disability)
Normotypical volunteers recruted on Preliminary Phase will be will carry out the ENDI tests in order to evaluate subtest design, ergonomics, understanding of instructions and identify any malfunctions. The observations gathered will enable the principal investigator to refine the digital design of the battery in collaboration with the publishing company.
Diagnostic Test: ENDI (Neuropsychological Evaluation in Intellectual Disability)
This neuropsychological battery comprises 15 subtests designed to assess language, memory, attention and executive skills. By analyzing changes in Trisomy 21 patients performance over time, the neuropsychologist can detect early signs of Alzheimer's disease.
Also known as: ENDI
Acceptability of individual subtests and the complete test battery
Acceptability will be estimated by The average completion time for the complete ENDI battery
Time frame: Through the study (completion of the full test battery), an average of 45 min
Acceptability of individual subtests and the complete test battery
Acceptability will be estimated by the Average completion time for each subtest of the ENDI battery
Time frame: Through the study (completion of the full test battery), an average of 45 min
Acceptability of individual subtests and the complete test battery
Acceptability will be estimated by the Percentage of complete completion of each ENDI subtest
Time frame: Through the study (completion of the full test battery), an average of 45 min
Acceptability of individual subtests and the complete test battery
Acceptability will be estimated by the Percentage of subjects having completed all ENDI battery subtests
Time frame: Through the study (completion of the full test battery), an average of 45 min
The convergent validity of ENDI tests
Correlation coefficient between ENDI scores and scores on DSQIID-F questionnaire. Scoring scale for the DSQIID-F questionnaire is from 0 to 53
Time frame: Through the study, an average of 16 months
The convergent validity of ENDI tests
Correlation coefficient between ENDI scores and scores on BPSD-DS questionnaire . The Scoring scale for BPSD-DS questionnaire is : for each dimension, frequency is rated from 0 to 4 and severity from 0 to 3 .
Time frame: Through the study, an average of 16 months
The convergent validity of ENDI tests
Correlation coefficient between ENDI scores and score on ISDC questionnaire. Scoring scales for ISDC questionnaire is for each dimension, frequency is scored from 0 to 4, severity from 0 to 3 and impact from 0 to 5
Time frame: Through the study, an average of 16 months
The convergent validity of ENDI tests
Correlation coefficient between ENDI scores and scores of CAMCOG II questionnaire. The Scoring scale for CAMCOG II questionnaire is from 0 to 106, the lower the score, the greater the impairment.
Time frame: Through the study, an average of 16 months
Start is estimated for Jul 2025; primary completion for Aug 2026, 13 months later.
Of 40 non-industry observational studies under Down Syndrome, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 61. This study's planned 13 months is below that.
Counting every sponsor, half of 55 studies reached it within 34 months; a quarter within 19 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Hospital, Nancy, France →